ABSTRACT Objective To assess the effects of enfuvirtide on pregnancy in albino rats and their fetuses. Methods Forty pregnant EPM 1 Wistar rats were randomly allocated into four groups: control (E) (distilled water twice/day), G1 (4mg/kg/day enfuvirtide), G2 (12mg/kg/day enfuvirtide), and G3 (36mg/kg/day enfuvirtide) groups. On the 20th day of gestation, the rats were anesthetized and subjected to cesarean section. Their blood was collected for laboratory analysis, and they were sacrificed. The offspring’s fragments of their kidneys, liver, and placentas and the maternal rats’ fragments of their lungs, kidneys, and liver were separated in the immediate postpartum period for light microscopy analysis. Results No maternal deaths occurred. In the second week at the end of pregnancy, the mean weight of the G3 Group was significantly lower than that of the G2 Group (p=0.029 and p=0.028, respectively). Analyzing blood laboratory parameters, the G1 Group had the lowest mean amylase level, and the G2 Group had the lowest mean hemoglobin level and the highest mean platelet count. In the morphological analysis, there were no changes in organs, such as the kidneys and liver, in both the maternal rats and offspring. Three maternal rats in the G3 Group had pulmonary inflammation in the lungs. Conclusion Enfuvirtide has no significant adverse effects on pregnancy, conceptual products, or functional alterations in maternal rats.

OBJETIVO: Avaliar a qualidade de vida (QV) de gestantes infectadas pelo HIV, utilizando o questionário HIV/AIDS - Targeted Quality of Life(HAT-QoL).MÉTODOS: Estudo descritivo que incluiu 60 gestantes atendidas no Núcleo Multidisciplinar de Patologias Infecciosas na Gestação (NUPAIG) - UNIFESP/EPM e na rede de referência da Secretaria Municipal de São Paulo. Foi realizado no período de fevereiro de 2011 a outubro de 2012. Foram coletadas variáveis sociodemográficas e clínicas de 60 gestantes infectadas pelo HIV, que responderam o questionário HAT-QoL, o qual incluiu 34 questões sobre qualidade de vida.RESULTADOS:A média de idade foi 30 anos e o tempo médio de infecção pelo HIV foi de 5,7 anos. Somente 8,3% das pacientes tinham contagem de células CD4 ≤200 células mm³ e 45% apresentavam carga viral indetectável. Os escores médios dos domínios variaram entre 47,5 e 83,7. Os domínios com escores mais baixos foram preocupações financeiras e preocupações com o sigilo. Os domínios com escores mais altos e menor impacto na qualidade de vida foram preocupações com a medicação e confiança no profissional.CONCLUSÃO: Neste estudo inicial, com 60 grávidas, concluímos que o HAT-QOL poderá contribuir para a avaliação da qualidade de vida na população de gestantes infectadas pelo HIV no Brasil.

PURPOSE: It was to assess the quality of life (QOL) of HIV-infected pregnant women using the HIV/AIDS - Targeted Quality of Life (HAT-QoL) questionnaire.METHODS:A descriptive study of 60 pregnant women attended at the Multidisciplinary Nucleus of Infectious Diseases During Pregnancy (NUPAIG) - UNIFESP/EPM and in the referral network of the Municipal Office of São Paulo, conducted from February 2011 to October 2012. Sociodemographic and clinical variables were collected from 60 HIV-infected pregnant women who answered the HAT-QoL questionnaire, which included 34 questions about quality of life.RESULTS:The average age was 30 years and the average period of HIV infection was 5.7 years. Only 8.3% of patients had a CD4 cell score of ≤200 cells/mm³ and 45% showed undetectable viral load. The average domain scores ranged from 47.5 to 83.7. The domains with the lowest scores were financial concerns and concerns about secrecy. The domains with the highest scores and lower impact on quality of life were concerns about medication and confidence in the professional.CONCLUSION: In this initial study with 60 pregnant women, we concluded that the HAT-QOL can contribute to the assessment of quality of life in the population of HIV-infected pregnant women in Brazil.

OBJETIVO: avaliar o efeito do uso crônico do amprenavir sobre as implantações, reabsorções, fetos, placentas e mortalidade materna e fetal da rata albina. MÉTODOS: 5 grupos de ratas albinas EPM-1 Wistar, prenhes, foram usados: 2 controles, Contr1 (controle do estresse) e Contr2 (controle do veículo), e três grupos experimentais, Exper1, Exper2 e Exper3, que receberam, respectivamente, 46, 138 e 414 mg/kg de peso de solução oral de amprenavir. Droga e veículo (propilenoglicol) foram ministrados por gavagem. Foram avaliados a evolução ponderal, número de implantações, de reabsorções, de fetos, de placentas e de óbitos intra-uterinos, o peso dos fetos e das placentas e malformações maiores. Foram retirados fragmentos de pulmões, rins, fígado e intestinos para avaliação histopatológica. RESULTADOS: observou-se, no grupo Exper3, tendência a menor ganho de peso materno durante a prenhez (p=0,07), mas o amprenavir não causou efeitos deletérios sobre o conteúdo intra-uterino. O efeito citotóxico da droga revelou-se nas análises histopatológicas de vísceras das ratas prenhes e na taxa de mortalidade materna: 50% nos grupos Exper1 e Exper2 e 70% no grupo Exper3. CONCLUSÃO: o amprenavir, em todas as doses administradas, mas especialmente na dose de 414 mg/kg de peso, mostrou ter efeito deletério sobre os pulmões, intestinos, rins e fígado maternos e aumentou significantemente o percentual de mortalidade materna.

OBJECTIVE: to evaluate the chronic effects of amprenavir on implantations, reabsorptions, fetuses, placentae, and maternal and fetal mortality in the albino rat. METHODS: five groups of EPM-1 Wistar pregnant rats were used: two controls: Contr1 (control of stress) and Contr2 (drug vehicle control), and 3 experimental groups that were treated once a day throughout gestation with 46mg/kg (Exper1), 138mg/kg (Exper2) and 414mg/kg (Exper3) of oral solution of amprenavir. The drug and the vehicle (propyleneglycol) were administered by gavage. The evaluations included maternal body weight gain, number of implantations, reabsorptions, fetuses, placentae and of intrauterine deaths as well as fetal and placental mean weight and major malformations. Fragments of lungs, kidneys, liver and intestines were collected and prepared for histopathological evaluation. RESULTS: Exper3 group tended to show lesser maternal body weight gain during gestation (P = 0.07), but amprenavir did not affect the intrauterine contents. The cytotoxic effect of the drug was observed with regard to the histopathological analyses of pregnant rat viscerae and to the maternal mortality rate: 50% in Exper1 and Exper2 groups, and 70% in Exper3 group. CONCLUSION: amprenavir exerted adverse side effects on maternal lung, gut, kidney and liver, and significantly increased maternal mortality rates in all administered doses and especially at 414 mg/kg.